Joseph Catanzaro
Stock Analyst at Piper Sandler
(1.88)
# 1,674
Out of 4,667 analysts
90
Total ratings
31.51%
Success rate
-7.53%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Overweight | $57 → $70 | $57.07 | +22.66% | 2 | Nov 7, 2024 | |
| GILD Gilead Sciences | Maintains: Overweight | $95 → $105 | $88.63 | +18.47% | 4 | Nov 7, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $51 → $52 | $45.76 | +13.64% | 8 | Nov 4, 2024 | |
| EPIX ESSA Pharma | Downgrades: Neutral | $15 → $2 | $1.73 | +15.61% | 2 | Nov 4, 2024 | |
| BMEA Biomea Fusion | Maintains: Overweight | $10 → $19 | $6.28 | +202.55% | 5 | Oct 31, 2024 | |
| EXEL Exelixis | Maintains: Overweight | $33 → $36 | $34.65 | +3.90% | 2 | Oct 30, 2024 | |
| IMTX Immatics | Initiates: Overweight | $19 | $7.80 | +143.59% | 1 | Oct 7, 2024 | |
| BDTX Black Diamond Therapeutics | Maintains: Overweight | $12 → $15 | $2.43 | +517.28% | 3 | Sep 23, 2024 | |
| AADI Aadi Bioscience | Downgrades: Neutral | $5 → $1.75 | $2.22 | -21.17% | 3 | Aug 27, 2024 | |
| TSBX Turnstone Biologics | Maintains: Overweight | $20 → $3.75 | $0.46 | +715.39% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $4.75 | $4.88 | -2.56% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $33.91 | +6.16% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 → $10 | $8.14 | +22.85% | 8 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $13.62 | +193.69% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $8.78 | +70.84% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 | $22.64 | +54.59% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2.25 → $3.5 | $0.87 | +302.25% | 3 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $1.63 | +176.07% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $6.50 | +361.54% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.71 | +638.01% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.07 | +86.92% | 3 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 | $54.14 | +93.94% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $0.98 | +920.41% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $7 | $2.53 | +176.68% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $50 | $19.17 | +160.82% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $4.08 | +341.18% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $25 | $2.84 | +780.28% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $21.15 | -5.44% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $1.05 | +42.86% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $0.50 | +1,908.03% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $4.67 | +649.46% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $3.18 | +1,786.79% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $6.49 | +177.35% | 3 | Apr 7, 2020 |
Revolution Medicines
Nov 7, 2024
Maintains: Overweight
Price Target: $57 → $70
Current: $57.07
Upside: +22.66%
Gilead Sciences
Nov 7, 2024
Maintains: Overweight
Price Target: $95 → $105
Current: $88.63
Upside: +18.47%
Halozyme Therapeutics
Nov 4, 2024
Maintains: Neutral
Price Target: $51 → $52
Current: $45.76
Upside: +13.64%
ESSA Pharma
Nov 4, 2024
Downgrades: Neutral
Price Target: $15 → $2
Current: $1.73
Upside: +15.61%
Biomea Fusion
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $6.28
Upside: +202.55%
Exelixis
Oct 30, 2024
Maintains: Overweight
Price Target: $33 → $36
Current: $34.65
Upside: +3.90%
Immatics
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $7.80
Upside: +143.59%
Black Diamond Therapeutics
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $2.43
Upside: +517.28%
Aadi Bioscience
Aug 27, 2024
Downgrades: Neutral
Price Target: $5 → $1.75
Current: $2.22
Upside: -21.17%
Turnstone Biologics
Aug 19, 2024
Maintains: Overweight
Price Target: $20 → $3.75
Current: $0.46
Upside: +715.39%
Aug 19, 2024
Maintains: Neutral
Price Target: $6 → $4.75
Current: $4.88
Upside: -2.56%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $33.91
Upside: +6.16%
Jul 29, 2024
Downgrades: Neutral
Price Target: $19 → $10
Current: $8.14
Upside: +22.85%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $13.62
Upside: +193.69%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $8.78
Upside: +70.84%
Jun 5, 2024
Maintains: Overweight
Price Target: $35
Current: $22.64
Upside: +54.59%
May 28, 2024
Upgrades: Overweight
Price Target: $2.25 → $3.5
Current: $0.87
Upside: +302.25%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $1.63
Upside: +176.07%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $6.50
Upside: +361.54%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $2.71
Upside: +638.01%
Apr 5, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.07
Upside: +86.92%
Mar 27, 2024
Maintains: Overweight
Price Target: $105
Current: $54.14
Upside: +93.94%
Mar 18, 2024
Maintains: Overweight
Price Target: $15 → $10
Current: $0.98
Upside: +920.41%
Mar 1, 2024
Maintains: Overweight
Price Target: $5 → $7
Current: $2.53
Upside: +176.68%
Feb 29, 2024
Maintains: Overweight
Price Target: $60 → $50
Current: $19.17
Upside: +160.82%
Feb 12, 2024
Initiates: Overweight
Price Target: $18
Current: $4.08
Upside: +341.18%
Oct 16, 2023
Maintains: Overweight
Price Target: $30 → $25
Current: $2.84
Upside: +780.28%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $21.15
Upside: -5.44%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $1.05
Upside: +42.86%
Mar 10, 2022
Maintains: Overweight
Price Target: $12 → $10
Current: $0.50
Upside: +1,908.03%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $4.67
Upside: +649.46%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $3.18
Upside: +1,786.79%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $6.49
Upside: +177.35%